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Biochemical and Molecular Epidemiology of
Human Cancer: Indicators of Carcinogen
Exposure, DNA Damage, and Genetic
Predisposition
by Curtis C. Harris,* Ainsley Weston,* James C. Willey,*
Glennwood E. Trivers,* and Dean L. Mann*
The primary goal of biochemical and molecular epidemiology is to identify individuals at high cancer
risk by obtaining evidence of high exposure to carcinogens, leading to pathobiological lesions in target
cells, and/or increased oncogenic susceptibility due to either inherited or acquired host factors. This
emerging and multidisciplinary area of cancer research combines epidemiological and laboratory ap-
proaches. Because DNA is considered to be an important target for modification by mutagens and car-
cinogens, damage to DNA can be used as an internal, molecular dosimeter of carcinogen exposure. The
reactive species ofthese carcinogens may directly bind to DNA to form adducts and may indirectly cause
secondary DNA lesions, e.g., via induction of free radicals and aldehydes. Highly sensitive and specific
methods have been developed to measure the minute amounts of DNA lesions and DNA repair products
found in biological specimens from humans exposed to carcinogens. For example, DNA adducts have been
measured in cells and tissues from people occupationally exposed to carcinogenic polycyclic aromatic
hydrocarbons. Antibodies recognizing carcinogen-DNA adducts have also been detected in human sera.
Inherited predisposition to cancer has been revealed by recent advances in molecular genetics, including
restriction-fragment-length polymorphism. For example, the hypothesis that rare alleles of the Ha-ras
proto-oncogene are associated with an increased risk of lung cancer is currently being tested. These
approaches afford the potential of biochemical and molecular epidemiology to predict disease risk for
individual persons, instead offor populations, and before the onset of clinically evident disease.
Introduction
The primary goal of biochemical and molecular epi-
demiology is to identify individuals at high cancer risk
by obtaining evidence ofhigh exposure to carcinogens,
leading pathobiological lesions in target cells and/or in-
creased oncogenic susceptibility due to either inherited
or acquired host factors. This emerging and multidis-
ciplinary area of cancer research combines epidemiol-
ogical and laboratoryapproaches (1-3). Clinicaland epi-
demiological studies have identified populations at high
cancer risk and, in many cases, also the etiological
agents, e.g., tobacco smoke as the major cause ofbron-
chogenic carcinoma. Laboratory studies have extended
these epidemiological findings by isolating and identi-
fying individual carcinogenic and cocarcinogenic agents
found in complex mixtures, e.g., polycyclic aromatic
hydrocarbons (PAH) in coal tar, diesel exhaust, and
tobacco smoke, and by discovering naturally occurring
and man-made carcinogenic and cocarcinogenic agents
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in our environment. Laboratory studies, especially
those using animal models, have also made major con-
tributions to our current understanding of the multi-
stage carcinogenic process that has been suggested by
clinical observations, human histopathologic, and in-
vestigations of animal models. Extrapolation ofcarcin-
ogenesis data to humans and the interindividual vari-
ationinoncogenicsusceptibilityinthehumanpopulation
have been previously discussed in detail (4,5).
This report willdiscuss opportunities and some ofthe
experimental approaches that show promise in identi-
fying individuals at the highest risk in a population of
people at high cancer risk. The concepts of tumor ini-
tiation, promotion, malignant conversion, and progres-
sion developed from studies in chemical carcinogenesis
(6-9) form the framework for this discussion. A sche-
matic representation of this multistage process is de-
picted in Figure 1. Humans are repeatedly exposed to
complex and variable mixtures that contain both initi-
ators and promoters, e.g., tobacco smoke (10), and to
complete carcinogens having both initiating and pro-
moting activities. Other factors, including host factors,HARRIS ETAL.
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FIGURE 1. Schematic representation of the multistage process of care
carcinogenesis are taken from studies ofexperimental carcinogenesis
are also known toinfluence cancerrisk(4,5,11-13). This
concept ofmultistage carcinogenesis provides a bridge
between experimental animal studies, in vitro human
cell carcinogenesis, and human carcinogenesis (14).
The earliest eventsinthemultistage processofchem-
ical carcinogenesis are considered to include exposure
tocarcinogens, transport ofthecarcinogentothetarget
cell, activation to ultimate carcinogenic metabolites, if
the agents are procarcinogens, and DNA damage lead-
ing to changes that result in the iniitiated cell (Fig. 1).
Each of these events has been extensively reviewed
(2,9) and will only be briefly discussed here.
Carcinogen Exposure and
Metabolism
Evidence of human exposure to carcinogens can be
indirectly obtained by detection of carcinogens in the
environment. Directevidence comesfrommeasurement
of carcinogens and/or their metabolites in body fluids
(15), such as urine (16-21), breast milk (22,23), seminal
fluid (24), and serum(15,25-27), andinsamplesoftissue
that may accumulate the carcinogen, such as fat for
lipophilic agents (28-30). Mutagenic activity found in
body fluids or extracts oftissues has also been used as
an indirect measurement of the putative presence of
carcinogens (22,31-33).
Once the carcinogen is transported into the target
Examples of factors that may either enhance or inhibit
cell, it may be enzymatically activated, generally to an
electrophilicmetabolite (34)and maybedetoxified, gen-
erally to more polar, water-soluble metabolites. Many
carcinogens in ourenvironment areprocarcinogensthat
require enzymatic activation. It has been recognized
during the last decade that many carcinogens require
multiple enzymatic steps to become activated to their
ultimate carcinogenic forn, and the activity ofthe rate-
limiting enzymatic reactionresponsible foractivationof
a carcinogen may differ among people and influence
their cancer risk. Therefore, the metabolic balance be-
tween activation and deactivation of a procarcinogen
and the covalent binding of its ultimate carcinogenic
metabolite to DNA are considered to be important
events in stages of carcinogenesis tumor termed initi-
ation and malignant conversion (Fig. 2).
Carcinogens can also be formed by endogenous re-
actions, e.g., nitrosation of amines to form N-nitrosa-
mines. Assaysto assess anindividual'scapabilityofpro-
ducing endogenous carcinogens are being developed
using safe substrates. For example, nitrosation of pro-
linetoformN-nitrosoproline, whichisexcretedinurine,
can be readily measured (35). Certain studies suggest
thatendogenousnitrosation maybeincreasedintobacco
smokers (36,37), whereas anotherstudydid notconfirm
these results (38).
Most chemical carcinogens are activated by oxidative
metabolism. The increasing number of types of cyto-
chrome P-450 that have been identified in laboratory
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FIGURE 2. Major determinants of amounts of carcinogen-DNA ad-
ducts.
animals (39) and in human tissues (40-42) may in part
explain interindividual differences in xenobiotic metab-
olism; interindividual variations in the activities of en-
zymes responsible forcarcinogen metabolism in various
human tissues and cells vary more than 1000-fold
(43,44). Substrate affinities and/or capacities of these
multiple forms differing from person to person is an-
other possible important variable factor.
Certain carcinogens and drugs may be metabolically
activated by the same enzymes, and indicator drugs,
such as debrisoquine, antipyrine, and dapsone, may
prove to be useful in probing genetic polymorphisms of
carcinogenmetabolism(43,45). Usingdebrisoquinemet-
abolic ratio-(debrisoquine/4-hydroxydebrisoquine in the
urine), Idle and co-workers(46) have found anincreased
rate of hydroxylation of debrisoquine in patients with
either bronchial cancer or hepatocellular cancer as com-
pared to that of noncancerpatients. In bronchial cancer
patients, this increase was found to be the case irre-
spective ofthe number of cigarettes consumed.
N-Acetylation polymorphism is the best-known ge-
neticcondition affectingthepharmacokinetics ofseveral
drugs, e.g., isoniazid, hydralazine, procainamide, and
dapsone(47). The acetylation statusiscontrolledbytwo
autosomal alleles at asingle locus, with slowacetylation
being manifest as a recessive trait. There is some evi-
dence that an increased urinary bladder cancer risk in
those occupationally exposed to carcinogenic aromatic
amines might be due to their slow N-acetylation phen-
otype (48,49). In contrast, the fast N-acetylation phen-
otype is associated with increased risk of colon carci-
noma (50).
Carcinogen-Macromolecular
Adducts
As noted in the previous section, metabolism of car-
cinogens from several chemical classes, including N-
nitrosamines, polycycic aromatic hydrocarbons, hydra-
zines, mycotoxins, and aromatic amines, have been in
human tissues and cells (51-54). The enzymes respon-
sible for the activation and deactivation of procarcino-
gens, the metabolites produced, and the carcinogen-
DNA adducts formed by cultured human tissues and
cells are generally qualitatively similar among donors
and tissue types. The DNAadducts and carcinogenme-
tabolites are also very similar to those found in most
laboratory animals, an observation that supports the
qualitative extrapolation of carcinogenesis data from
the laboratory animal to the human situation. Because
studies using experimental animals generally indicate
that their cancer risk is influenced by the capacity for
metabolic activation ofprocarcinogens, it is likely that
a similar relationship exists for humans (55,56).
Table 1 lists examples ofprocarcinogens activated by
cultured human tissues into metabolites that bind co-
valentlyto DNA. Although the majorDNAadducts are
qualitativelysimilar, quantitativedifferenceshavebeen
found among individuals and their various tissues, and
in outbred animals. These differences in enzymatic ac-
tivities and number of DNA adducts generally range
from 10- to 150-fold among humans and are ofthe same
order of magnitude found in pharmacogenetic studies
of drug metabolism.
Results from in vivo and in vitro studies discussed
above serve as a basis for investigations in biochemical
and molecular epidemiology. For example, the obser-
vation that the carcinogen-DNA adducts formed in cul-
tured human tissues are generally the same as those
found in experimental animals in which these chemicals
induce cancer has encouraged investigators to search
for DNA adducts in biological specimens obtained from
people exposed to either specific carcinogens such as
benzo[a]pyrene orchemotherapeuticagents. Therecent
development of highly sensitive methods for detecting
carcinogen-DNA adducts has made this search possible
(Table 2). Methods currently used include 'P-nucleo-
tidepostlabelingandchromatography (57), synchronous
scanning fluorescent spectrophotometry (58,59), mass
spectrometry(60,61), andimmunoassays(62-65). These
methods are being used to measure carcinogen-macro-
Table 1. Interindividual variation in carcinogen binding to DNA
in cultured human tissues.a
Fold variation in carcinogen binding
Tissue BP AFB1 DMNA 1,2-DMH AAF DMBA
Esophagus 99 70 90
Trachea 6
Bronchus 75 120 60 10 18 50
Peripheral lung 3
Liver 12
Duodenum 31
Colon 197 150 145 80
Bladder 68 127 14
Endometrium 70
aThe highest variation among people was reported for benzo-
[a]pyrene (BP), aflatoxin B1 (AFB1), dimethylnitrosamine (DMNA),
1,2-dimethylhydrazine (1,2-DMN), acetylaminofluorene (AAF), and
7,12-dimethylbenzanthracene (DMBA), carcinogen-DNA binding in
cultured human tissues (14,44). The number of cases studied ranges
from less than 10, e.g., peripheral lung, to more than 100, e.g., colon
in the various investigations.
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Table 2. Examples of assays to measure carcinogen-
marcromolecular adducts.
Cellular DNA adducts
Nonhydrolyzed
Immunoassays
Fluorimetry
Other
Hydrolyzed (concentration, e.g., HPLC or immunocolumn,
followed by):
32P-Postlabeling
Immunoassay
Fluorimetry
Other
Urinary base adducts
Protein adducts
Hemoglobin
Albumin
molecular adducts in cells from people exposed to car-
cinogenic chemicals (Tables 3-6) and cancer chemo-
therapeutic agents (66). Although these techniques
measure DNA lesions considered to be important in
carcinogenesis, this is a multistage process, so it is un-
likely that DNA adducts will be precise quantitative
predictors of cancer risk.
Our research group has primarily used two comple-
mentary approaches formeasuringPAH-DNA adducts:
ultrasensitive enzyme radioimmunoassay (USERIA)
and synchronous scanning fluorescent spectrophoto-
metry (SFS). These assays have been validated using
animal models and cells in vitro (67,68). The aim of our
initial epidemiological studies has been to determine if
PAH-DNA adducts and serum antibodies recognizing
these adducts canbedetected inbiologicalsamples from
people exposed to high levels of PAH, e.g., coke oven
workers and roofers.
Among a group of 27 U.S. coke-oven workers who
hadbeenemployed forbetween5and30 years, 18(67%)
were found to be carrying significant levels of adducts
in their peripheral blood lymphocytes (69) (Table 3).
Within this group, 12 were smokers and 15 were non-
smokers; ofthe smokers, 9 (75%) were positive, and of
the nonsmokers, 9 (60%) were positive. Sevenmembers
ofthis group were known to workin environments con-
taining high levels ofbenzene-soluble particulates, and
6 of them (86%) were found to be positive in the
USERIA test. In a study involving 3 groups, i.e. 28
roofers, 20 foundry workers, and 9 laboratory workers,
7 (25 and 35%) ofthe samples from each ofthe groups
subjected to PAH exposure and 2 (22%) of the nonin-
dustrially exposed individuals were found to be positive
by USERIA (70). Within a group of38 Norwegian coke-
over workers, 13 (34%) individuals were found to have
detectable, peripheral blood lymphocyte DNA adducts
(70); among these, 6 were smokers. Following a3-week
vacation period, 9 out ofthe group of 13 had lower but
still detectable levels ofadducts in the USERIA assay.
These assays employed a rabbit antiserum developed
by immunization with benzo[a]pyrene diol epoxide
(BPDE)-DNA (71). The specificity of the rabbit anti-
serum used in these tests was determined by the ex-
amination ofthe extenttowhichitsreactivitytoBPDE-
DNA wasinhibitedbytherelated adductsformedwhen
benz[a]anthracene diol epoxide (BADE) and chrysene
diol epoxide (ChDE) were reacted with DNA in vitro.
The inhibition curves show that both BADE-DNA and
ChDE-DNAcross-reactwiththeanti-BPDE-DNAanti-
serum to a significant extent, but the antiserum does
not react with carcinogens of other chemical classes,
e.g., aromaticaminesandmycotoxins(67,68,71). There-
fore, the rabbit antiserum recognizes certain other
Table 3. Detection of DNA adducts in human tissues and cells by enzyme immunoassays.
Approximate level of
No. positive/ adducts per 108
Immunoassay Origin of DNA No. tested, % nucleotides Reference
BPDE-DNA antigenicity Placenta (102); Santella et al.,
Smokers 23/25 (92) 60 unpublished data
Nonsmokers 22/25 (88) 20
Lung
Lung cancer patients 5/16 (31)
COPD 0/1 (0) 5-10 (103)
Control or other cancer 0/10 (0)
Coke oven workers
Finland 7/20 (35) 10 (20)
Norway 13/36 (36) 3-490
USA 18/27 (67) 75-420 (69)
Roofers 7/28 (25) 20 (70)
Foundry workers 7/20 (35) 20 (70)
06-methylguanine Chinese cancer patients: esophageal and
stomach mucosa 27/37 (73) < 1-10 (104)
European cancer patients: esophageal and
stomach mucosa 7/14 (50) <2 (104)
06-ethylguanine Chinese and European cancer patients 0/51 (0) (104)
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Table 4. Detection of DNA adducts in human tissues and cells by fluorescent assay.
Adduct
PAH-DNAa
7-Methylguanine
06-methylguanine
Origin of DNA
Lymphocytes
Coke oven workers
USA
Norway
Liver
DMN poisoning
MeBr poisoning
Reye's syndrome
Kidney
MeBr poisoning
Liver
DMN poisoning
MeBr poisoning
Reye's syndrome
Kidney
MeBr poisoning
aSpectra similar to benzo[a]pyrene tetrol.
No. positive/
No. tested, %
31/41 (76)
4/13 (31)
2/2 (100)
0/1 (0)
0/3 (0)
Approximate level of
adducts per 108
nucleotides
10-100
15-80
5 x 105
0/1 (0)
2/2 (100)
0/1 (0)
0/3 (0)
1 x 105
0/1 (0)
Table 5. Detection ofputative DNA adducts in human tissue and cells by 3P-postlabeling analysis.
Approximate level of
No. positive/ adducts per 108
Adduct Origin of DNA No. tested, % nucleotides Reference
Unknown DNA Placenta
(CSC-related) Smokers 29/30 (97) < 0.1-1.4 (102,106)
Nonsmokers 3/24 (12)
Unknown DNA Oral mucosa
Betel nut chewers 22/22 (100) < 0.1-10 (107)
Tobacco chewers 22/22 (100)
Inverted smokers 15/15 (100)
Ethnic controls 19/19 (100)
Bone marrow cells
Smokers 4/4 (100) < 0.1-9 (108)
Nonsmokers 6/6 (100)
Bronchus
Smokers 1/1 (100) < 17-29 (106)
Nonsmokers 0/1 (100)
Table 6. Detection of protein adducts in human tissues and cells by physical assays.
Origin of No. positive/ Approximate level
Adduct hemoglobin (hb) No. tested, % detected, pmole/g Reference
Aminobiphe nyl-hb Smokers 30/30 (100) 0.37-1.5 (109)
Nonsmokers 38/38 (100) 0.04-0.64
Ethylene-oxide Smokers 11/11 (100) 217-690 (61)
(ETO)valine Nonsmokers 14/14 (100) 27-106
Ethylene-oxide valine EtO workers 7/7 (100) 20-7700 (60)
Controls 3/3 (100) 30-930
Ethylene-oxide histidine EtO workers 7/7 (100) 550-8000 (60)
Controls 3/3 (100) 530-1600
Reference
(69)
(59)
(105)
(105)
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PAH-DNA adducts and provides a wide screen for de-
tecting DNA modified by certain PAHs.
Fluorimetricassayshavealsobeenusefulindetecting
PAH-DNA adducts (Table 4). For example, DNA sam-
ples isolated from the peripheral blood lymphocytes of
41 U.S. coke-oven workers were examined by SFS us-
ing a fixed wavelength interval of34 nm to simultane-
ouslydrivetheexcitationandemissionmonochromators
(69). Fluorescent emissionsthat were similartothe sig-
nals generated for either authentic BPDE-DNA ad-
ducts or BPDE-DNA adducts isolated from mouse skin
were detected in 31 cases (75%). However, two types
of complex spectra were detected: sharp peaks (24%)
and broad peaks (51%) (Fig. 3). These data suggest the
presence ofmore than one fluorophore inthese samples
that contribute to the signal and therefore do not allow
for precise quantitation without further separation
methodology, as will be discussed below. However,
presence ofthe sharper type ofpeaks with fluorescent
emission maxima in the region expected for pyrene
(374-384 nm) suggest the presence in these samples of
BPDA-DNAadducts. WhenDNAsamplesfrom38Nor-
wegiancoke-ovenworkers wereexaminedbySFS, only
4 (10%) were found to have fluorescent emissions be-
tween 374 and 384 nm (20). These corresponded to 4 of
the 13 samples that were positive in the USERIA, and
3 (75%) were smokers. Following a vacation period (3
weeks), however, no fluorimetric evidence forthe pres-
ence ofBPDE-DNA adducts was found in this group of
coke-ovenworkers, and substantial decreases were also
found by USERIA.
The use of a physical assay (SFS) in these studies
complements the immunoassays, and it appears that
each ofthe assays demonstrate the formation ofarange
of PAH-DNA adducts in many ofthe individuals stud-
ied. Data obtained in any individual assay are clearly
less reliable than ifthose data are substantiated by du-
z
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FIGURE 3. Synchronous fluorescence spectra of synthetic BPDE-
DNA (..) adducts and DNA samples from peripheral blood lym-
phocytes of coke-oven workers. The broad peak (-) was found
to be carrying adducts corresponding to 1.2 fmole BPDE/,ug DNA
by USERIA and the sharp peak (---) 26.5 fmnole BPDE4Lg DNA.
plication in an alternative system. Positive results ob-
tained by both SFS and USERIA strongly suggest the
presence ofthe activated BP or closely related moiety
inagiven DNAsample. Twotypesoffluorescentsignal,
a broad type and a sharp type, are detected by SFS.
The sharp type is probably indicative of a relatively
large concentration ofBPDA-DNA adducts and this as-
sertion is substantiated by comparison ofthe SFS and
USERIA, where data for both assays are available. In
addition, ithasbeenpossible tofractionate lymphocyte-
DNA samples by high pressure liquid chromatography
for SFS and in some cases clearly define the identity of
the fluorescent signals (68).
The32P-postlabelingmethoddevelopedbyRanderath
and co-workers (57) enables the fingerprinting ofmod-
ified deoxynucleotides isolated from tisses of experi-
mental animals and humans exposed to complex mix-
tures of environmental carcinogens. This is proving to
be a highly sensitive screening method because detec-
tion ofboth previously characterized DNA adducts and
unknown adducts is possible (Table 5). In fact, more
thannine unidentified putative DNAadductshave been
detected by this method in bone marrow, placenta, and
lung tissue from cigarette smokers ornonsmokers. The
chemical identification of these unknown spots on the
chromatograms andthe precise quantitation awaits fur-
ther study.
Although hemoglobin and albumin are not considered
targets for the pathobiological effects of carcinogens,
these macromolecules have certain advantages for the
molecular dosimetry of exposure to carcinogens. For
example, red blood cells have a lifetime of about 120
days in humans, so the levels ofcarcinogen-hemoglobin
adductsmaybeanintegrative measure ofexposuredur-
ing a period ofnearly 4 months. In addition, these pro-
tein adducts, unlike DNA adducts, are not considered
to be repaired in the circulating red blood cells, and
milligram quantities can be obtained from a few milli-
liters of blood. Ehrenberg and co-workers (72) pi-
oneered this area ofresearch foralkylatingagents such
as ethylene oxide. The amounts of ethylene oxide and
4-aminobiphenyl-hemoglobin adducts are substantially
increased in tobacco smokers compared to nonsmokers
(Table 6).
Interestingly, antibodies directed against authentic
BPDE-DNA adducts have been found in human sera
(69). Antibody binding patterns were established for
these samples, and it was found that 11 (27%) of the
individuals in one study had developed antibodies to
BPDE-DNA adducts. In a separate study (20) where
serum was obtained from 38 donors at two sampling
times (9 months apart), 12 (32%) and 13 (34%) serum
samples, respectively, were found to contain antibodies
that were directed against synthetic BPDE-DNA ad-
ducts (20).
Analysesofhumanantiserabyenzymeimmunoassays
showed that antibodies are produced against a range of
PAH-DNA adducts (Newman et al., unpublished re-
sults). Selected sera were found to contain antibodies
specific for BPDA-DNA, ChDE-DNA, and BADE-
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DNA adducts, suggesting that these adducts each pos-
sess at least one immunologically unique epitope. In
addition, the results ofantigen-competitive enzyme im-
munoassays showedthepresenceofbothadduct-specific
and cross-reactive antibodies in some sera. Cross-reac-
tivity was documented between BADE-DNA and
ChDE-DNA adducts and between ChDE-DNA and
BPDE-DNA adducts, but not between BADE-DNA
and BPDE-DNA adducts. Thus, the presence of two
different cross-reactive epitopes is suggested, one on
BPDE-DNA and one on BADE-DNA, both of which
are shared with ChDE-DNA. Computer simulations of
these adducts using methods described by Brooks (73)
are being compared in an attempt to more fully under-
stand the structural variations between these com-
pounds that amount for the observations described.
Current dogma has directed our efforts to measuring
adducts formed by the direct interaction between the
activated carcinogen metabolite(s). However, carcino-
gens may also exert their oncogenic effects via indirect
damage to macromolecules such as carcinogen-induced
formation of superoxides, which cause DNA damage
including thymine glycol and other altered nucleic acid
structures. This induction ofthe pro-oxidant state, i.e.,
increased concentrations ofactive oxygen, organic per-
oxides, andradicals, mayalsobe ofimportance intumor
promotion (74). Both immunoassays (63,75) a-nd32P-
postlabeling assays (76) arebeingdeveloped tomeasure
radiation- and radical-induced DNA damage.
Genetic Predisposition to Cancer
Due to the biologically diverse, genetically hetero-
geneous, human population and the multistep nature of
the carcinogenic process, there are differences in sus-
ceptibility between individuals to the oncogenic effects
of environmental carcinogens.
Investigation ofindividuals with multiple tumors has
led to the discovery of several hereditary conditions of
increased cancer incidence (Table 7) (77,78). These dis-
eases may be transmitted by single-gene, polygenic, or
chromosomal mechanisms. Some hereditary conditions
predispose only one type of tissue of neoplasia (e.g.,
actinic keratosis predisposes to basal cell carcinomas of
theskinandfamilialpolyposiscolipredisposestotumors
in the gastrointestinal tract), while other hereditary
conditions predispose to multiple tumors in different
tissues (e.g., hereditary retinoblastoma, Bloom's syn-
drome, and ataxia telangiectasia).
Most known hereditary causes of multiple tumors
were discovered because they manifested as dramatic
clinical syndromes with a Mendelian pattern of inher-
itance. In some ofthese diseases, host susceptibility to
specific environmental agents has been determined,
e.g., ultraviolet radiation as a cause of skin cancer in
patients with xeroderma pigmentosum. In contrast to
these rather rare conditions, most common types ofhe-
reditarymultiple cancer occurinfamilialpatternswhich
probably have a polygenic basis (79).
Analysis of certain epidemiological data has sug-
Table 7. Examples of inherited disorders associated with an
increased risk of cancer (77).
Constitutional chromosomal abnormalities
Down's syndrome
Klinefelter's syndrome
Mendelian traits
Inherited cancer syndromes
Retinoblastoma
Familial polyposis coil
Multiple endocrine neoplasia syndromes
Inherited preneoplastic states
DNA repair defects and chromosomal instability syndromes:
Xeroderma pigmentosum, Fanconi, Bloom's, ataxia
telangiectasia
Disturbances oftissue organization
Hamartomatous syndromes: Peutz-Jegher's, Cowden,
neurofibromatosis
Other conditions in which disturbance oftissue proliferation,
differentiation or organization is associated with increased
cancer risk: disorders of skin keratinization (?), a-i-anti-
trypsin deficiency (?)
Immune deficiency syndromes
Metabolic variation:
Albinism
Aryl hydrocarbon hydroxylase inducibility (?)
Variations in estrogen metabolism (?)
Multifactorial predisposition
Ethnic cancer differences
Familial cancer aggregations
gested a two-hit mutation model ofcarcinogenesis (80).
A genetic predisposition may be due to inheritance of
the first autosomal mutation so that only one additional
genetic event is required. Therefore, these individuals
may already have initiated cells due togermline genetic
lesions. Retinoblastomais anexampleofahumantumor
in which a pair of tumor suppressor genes located at
the chromosomal region 13q14 and loss (inactivation) of
these diploid genes leads to tumor formation (81). In
this context, diploidy can be viewed as a protective
genetic mechanism. Possible mechanisms producing
homozygosity or hemizygosity at the retinoblastoma lo-
cus in tumor cells include chromosomal nondisjunction,
nondisjunction and reduplication, mitotic recombina-
tion, deletion, gene inactivation, and mutation. One of
these mechanisms, mitotic recombination, may also be
important in the genetic predisposition to cancer found
in Bloom's syndrome.
Evidenceforthesepresumed dominant-acting"tumor
suppressor" genes has arisen primarily from epide-
miological studies discussed above; molecular analysis
of polymorphic DNA restriction fragments showing a
reduction to homozygosity of chromosome 13 found in
retinoblastoma and osteosarcoma (82), of chromosome
11 inWilm's tumor (83-86) and bladdercancer(87), and
ofchromosome 22 in acoustic neuroma (88); and studies
with human cell hybrids in the field of somatic cell ge-
netics (89-91). Recently, a DNA with properties ofthe
Rb gene, whose loss correlates with the development
of retinoblastoma and osteosarcoma, has been isolated
(92). Stanbridge and co-workers (93) have alsoreported
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1. DNA digestion by restriction enzymes (R. and R2)
R2 R, R2
DNA 5' _ 3'
2. DNA electrophoresis and hybridization
Lose RI Gain RI Deletion Insertion
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t Increasing
Molecular
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"Site" "Insertion/Deletion"
Polymorphism Polymorphism
FIGURE 4. Schematic representation of DNA polymorphism ana-
lyzed by restriction enzyme digestion, DNA electrophoresis, and
DNA hybridization.
suppression of tumorigenicity with continued expres-
sion ofthe C-Ha-ras oncogene in EJ bladder carcinoma-
human fibroblast hybrid cells. This finding suggests
that, even in the presence of an activated proto-onco-
gene, tumor suppressor genes are dominant-acting.
New experimental approaches to identify people ge-
netically predisposed to cancer are being evaluated,
e.g., restriction enzyme DNAfragment-length analysis
of genetic polymorphism (RFLP). Until recently, ge-
netic predisposition could be assessed only by meas-
uring gene products, e.g., histocompatibility antigens
on cell surfaces, isoenzymes and, as discussed earlier,
pharmacogenetic phenotype. Advances in molecular bi-
ology now have made it possible to measure genetic
polymorphism atthe DNAlevel, whichgreatlyexpands
the potential ofassays ofpolymorphisms in biomedical
research. Genetic polymorphism can be measured by
restriction enzyme analysis and DNA hybridization
(Fig. 4) (94). RFLPs are oftwo types: site orinsertion/
deletion polymorphism. In the case of site polymorph-
ism, the recognition site for a given restriction enzyme
in a particular region of DNA either appears or disap-
pears as the result ofpoint mutation. Accordingly (Fig.
4), in the site-absent phenotype, one large fragment
instead of two smaller fragments is observed. Con-
versely, inthe site-present phenotype, threefragments
(one of expected size and two smaller) instead of two
fragments are seen.
In the case of insertion/deletion polymorphism, var-
iation in fragment length is the result of insertion or
deletion ofDNA sequences and will be detected by any
restriction endonuclease that possesses recognition
sitestightly spanningtheregion ofsequence alteration.
Because the insertions or deletions can assume a con-
tinuum of lengths, more than two alleles are possible.
This RFLPapproachhasalreadybeenprovenbeneficial
in identifying individuals with a genetic predisposition
to a variety ofdiseases, including retinoblastoma, non-
insulin-dependent diabetes mellitus, Huntington's dis-
ease, and hemoglobinopathies (95). The same molecular
approachusingspecific DNAprobes, e.g., foroncogenes
andectopichormones, isnowbeingstudiedtodetermine
its potential in identifying persons with a genetic pre-
disposition to cancer. The human Ha-ras proto-onco-
gene may prove useful for these studies because it con-
tains a hypervariable insertion/deletion polymorphism.
The molecular basis for this insertion/deletion poly-
morphism is a region of 30 to 100 tandem nucleotide
repeats with a28 base pair consensus sequence aligned
head-to-tail that is approximately 1 kilobase down-
streamfromthe structuralgeneofHa-ras. Thefunction
of this variable tandem repeat (VTR) is unknown but
it may have gene enhancer activity and appears to be
inherited in a Mendelian fashion. An increased fre-
quency of rare alleles at this locus has been found in
certain cancer patients, including those with bladder
carcinoma (96) and breast carcinoma (97). Preliminary
data indicates that rare alleles are also more frequent
in patients with bronchogenic carcinoma (Weston et al.,
unpublished results). Evidence for (98) and against (99)
Ha-ras involvement in sporadic and familial melanoma
has been reported.
Although RFLP analysis should help to provide the
general location of genes involved in common malig-
nancies, in most cases more powerful tools will be re-
quired to precisely identify them. The recent develop-
ment of pulsed-field electrophoresis, combined with
innovative cloning techniques (100,101) should prove
valuable in gene isolation.
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